L-A Martin

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

Iván Plaza-Menacho, Andrea Morandi, David Robertson et al. · Oncogene · 2010 · 143 citations

Medicine, Cancer Biology, Oncology +16

The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling

L-A Martin, Sunil Pancholi, Christina M.W. Chan et al. · Endocrine Related Cancer · 2005 · 82 citations · Full text

Medicine, Endocrinology, Oncology +12

Abstract P3-03-09: Resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome

L-A Martin, Sunil Pancholi, Ricardo Ribas et al. · Cancer Research · 2017 · 22 citations

Medicine, Oncology, Pharmacology +17

The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling

L-A Martin, Sunil Pancholi, Ian Farmer et al. · Breast Cancer Research · 2005 · 14 citations · Full text

Medicine, Cancer Biology, Oncology +15

60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B

Jenny Furlanetto, F Marmé, C. Thode et al. · Annals of Oncology · 2022 · 11 citations · Full text

Medicine, Gynecology, Oncology +17